French multicenter phase III study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at two years (FNLCC-GORTEC)
Date 2006, Vol 10, Num 4, pp 214-215Revue : Cancer radiothérapie : journal de la Société française de radiothérapie oncologiqueDOI : 10.1016/j.canrad.2006.05.006Aucun résumé disponible
Exporter
Citer cet article
French multicenter phase III study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at two years (FNLCC-GORTEC). Cancer Radiother. 2006;10(4):214-215.